Luminopia Inc.

About Luminopia Inc.

Luminopia is a company focused on developing innovative therapies for amblyopia (lazy eye) in children. Their mission is to provide an engaging and effective treatment alternative to traditional methods like patching, using virtual reality (VR) technology to improve vision while making the process enjoyable for children aged 4-12.

Products & Services

Luminopia Binocular Therapy:An FDA-cleared VR-based therapy for amblyopia in children aged 4-12, allowing them to watch TV shows through a VR headset for 1 hour a day, 6 days a week. Clinically proven to improve vision in as early as 4 weeks, with high engagement and parental preference over traditional patching.

Specialties

Amblyopia Treatment Virtual Reality Therapy Binocular Therapy Pediatric Ophthalmology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 16000000 MR: - FA: $16 million FAN: 16000000	D: 2023-06-27 FD: 2023-06-27	5 investors

Series A Latest

2023-06-27

$16.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Scott Xiao

Co-Founder and CEO

B

Brion Raymond

CBO

D

Drew Mowery

VP of Commercial Strategy

H

Hank Wu

COO

R

Richard Plank

National Sales Director

S

Shelley Hancock

Sr Director, Medical Affairs

View 15 more team members with Pro

Unlock Full Team Directory

Recent News

Luminopia Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised